Pipeline

Introduction of Three Negative Breast Cancer (TNBC)
       Breast cancer is the first leading cause of cancer-related morbidity and mortality among women. In 2012, 1,676,600 women worldwide were diagnosed with breast cancer, and 521,900 women died from it. There is an obvious geographical difference in the incidence of breast cancer. It is the highest in Europe and America, while is relatively low in Asia and Africa.

Introduction of Gastric Cancer

        Gastric cancer is the fifth most common cancer and the third leading cause of cancer death worldwide. With > 950,000 new diagnoses each year and ~ 720,000 deaths in 2012, gastric cancer represents 7% of global cancer incidence. Although the global incidence of gastric cancer is declining, it remains highly prevalent in Asia when compared to the West. China is one of the countries with the highest incidence of gastric cancer and accounts for > 40% of all new gastric cancer cases in the world. Indeed, gastric cancer is the second leading cause of cancer mortality in China.

 

Introduction of Colon Cancer

        Colon cancer is the third most commonly diagnosed cancer in males and the second in females, with an estimated 1.4milli on cases and 693,900 deaths occurring in 2012. Other high rates are in Europe, Oceania, and North America. The lowest rates are found in Africa, some Asian countries, and Latin America and the Caribbean. Colon cancer is the third most common cancer diagnosed among U.S. men and women with ~130,000 new cases diagnosed each year.


Innovative Candidate Compounds for Anti-cancer
        ABP-431 is a First-in-Class drug candidate for anti-tumor, which is in a new target and a new molecular entity. ABP-431 has a selective anti-tumor efficacy for certain cancer types, including gastric cancer, triple-negative breast cancer, and colon cancer, both in vitro and vivo studies.